Monitor the EVX-01 three-year data presentation at ESMO in October 2026 as the next major catalyst. The current cash runway into H2 2027 provides a long enough window for data readouts but leaves no margin for delays. The ATM program remains available for up to $45.5M in additional sales, creating ongoing dilution risk. No near-term trading catalyst until ESMO.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $3.28entry
- T+1 · 3mo ago +0.91%α +0.51% · $3.31
- T+5 · 3mo ago −3.96%α −5.08% · $3.15
- T+20 · 2mo ago −0.30%α −0.30% · $3.27
- T+60 · 4d ago −16.46%α −15.38% · $2.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY), cash burn continues with $14.0M cash on hand funding operations into H2 2027. Pipeline progress includes upcoming 3-year EVX-01 data at ESMO and new preclinical programs (EVX-04, EVX-05, EVX-V1), but the company remains pre-revenue with no near-term catalysts that change the fundamental cash-burn story. A post-period ATM sale of $1.5M adds modest dilution. The combination of steady cash burn, pre-revenue status, and pipeline milestones that are months away suggests limited near-term catalysts for the stock.
Key Facts
- Net loss of $3.7M for Q2 2026, improved from $4.8M in Q2 2025
- Cash and cash equivalents of $14.0M as of June 30, 2026, down from $18.4M at March 31, 2026
- Cash runway unchanged: funds operations into second half of 2027
- No revenue recorded for Q2 2026
- Post-period: sold 505,005 ADSs at $3.1533/ADS for net proceeds of ~$1.5M via ATM
- Upcoming catalyst: 3-year clinical data for EVX-01 at ESMO Congress 2026 in October
- Pipeline expansion with EVX-05 (glioblastoma) and preclinical data for EVX-04 (AML) and EVX-V1 (CMV)
- Total equity declined to $9.5M from $17.0M at Dec 31, 2025
- R&D expenses $2.3M, G&A expenses $1.5M for Q2 2026
Financial Impact
Net loss of $3.7M in Q2 2026; cash burn of $8.7M in H1 2026; post-period ATM raised ~$1.5M
Risk Factors
- Cash burn continues with no revenue; additional ATM sales will dilute existing shareholders
- Pre-revenue clinical-stage company with no guaranteed path to commercialization
- Pipeline milestones (EVX-01 data, EVX-04 IND filing) are months away and binary in nature
- Equity declined from $17.0M to $9.5M in six months; negative equity trajectory if losses persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (EVAX), Batch item 1 | 0001171843-26-005672 |
| Document: f6k_082026.htm | 0001171843-26-005671 |
| Document: 0001171843-26-005672-index-headers.html | 0001171843-26-005672 |
| Document: 0001171843-26-005672-index.html | 0001171843-26-005672 |
| Document: 0001171843-26-005672.txt | 0001171843-26-005672 |
| 6-K Filing (EVAX), Batch item 6 | 0001171843-26-005671 |
| Exhibit: ex_1006845.htm | 0001171843-26-005672 |
| Document: evax20260819_6k.htm | 0001171843-26-005672 |
| Document: 0001171843-26-005671-index-headers.html | 0001171843-26-005672 |
| Document: 0001171843-26-005671-index.html | 0001171843-26-005672 |
| Document: 0001171843-26-005671.txt | 0001171843-26-005672 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers